These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34112481)

  • 1. Reply to "How important is the second dose of the COVID-19 mRNA vaccine?".
    Shaker MS; Phillips E; Blumenthal KG; Abrams EM; Banerji A; Oppenheimer J; Vander Leek TK; Mack DP; Wickner PG; Singer AG; Khan DA; Greenhawt M
    J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2537-2539. PubMed ID: 34112481
    [No Abstract]   [Full Text] [Related]  

  • 2. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
    Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
    JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How important is the second dose of the COVID-19 mRNA vaccine?
    Liu AY
    J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2537. PubMed ID: 34112480
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. Reply.
    Absalon J; Koury K; Gruber WC
    N Engl J Med; 2021 Apr; 384(16):1578. PubMed ID: 33596351
    [No Abstract]   [Full Text] [Related]  

  • 6. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. Reply.
    Barda N; Dagan N; Balicer RD
    N Engl J Med; 2021 May; 384(20):1970. PubMed ID: 33882227
    [No Abstract]   [Full Text] [Related]  

  • 7. Boosting maternal and neonatal humoral immunity following SARS-CoV-2 infection using a single messenger RNA vaccine dose.
    Nevo L; Cahen-Peretz A; Vorontsov O; Frenkel R; Kabessa M; Cohen SM; Hamrani A; Oiknine-Djian E; Lipschuetz M; Goldman-Wohl D; Walfisch A; Kovo M; Neeman M; Yagel S; Wolf DG; Beharier O
    Am J Obstet Gynecol; 2022 Sep; 227(3):486.e1-486.e10. PubMed ID: 35430228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons. Reply.
    Meaney-Delman DM; Ellington SR; Shimabukuro TT
    N Engl J Med; 2021 Oct; 385(16):1536. PubMed ID: 34496198
    [No Abstract]   [Full Text] [Related]  

  • 9. Accelerate Coronavirus Disease 2019 (COVID-19) Vaccine Rollout by Delaying the Second Dose of mRNA Vaccines.
    Plotkin SA; Halsey N
    Clin Infect Dis; 2021 Oct; 73(7):1320-1321. PubMed ID: 33502467
    [No Abstract]   [Full Text] [Related]  

  • 10. Serological findings following the second and third SARS-CoV-2 vaccines in lung transplant recipients.
    Bárczi E; Varga V; Nagy A; Eszes N; Jáky-Kováts Z; Müller V; Bohács A
    Immun Inflamm Dis; 2022 Aug; 10(8):e646. PubMed ID: 35894705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced BNT162b2 Messenger RNA Vaccine Response in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Naive Nursing Home Residents.
    Canaday DH; Carias L; Oyebanji OA; Keresztesy D; Wilk D; Payne M; Aung H; St Denis K; Lam EC; Rowley CF; Berry SD; Cameron CM; Cameron MJ; Wilson B; Balazs AB; Gravenstein S; King CL
    Clin Infect Dis; 2021 Dec; 73(11):2112-2115. PubMed ID: 33993265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Reply to "Effectiveness of mRNA Covid-19 vaccine in healthcare workers"].
    Núñez-López C; González-de Abreu JM; Pérez-Blanco V; Díaz-Menéndez M;
    Enferm Infecc Microbiol Clin (Engl Ed); 2022 May; 40(5):284-285. PubMed ID: 35577450
    [No Abstract]   [Full Text] [Related]  

  • 13. Effectiveness of a bivalent mRNA vaccine dose against symptomatic SARS-CoV-2 infection among U.S. Healthcare personnel, September 2022-May 2023.
    Plumb ID; Briggs Hagen M; Wiegand R; Dumyati G; Myers C; Harland KK; Krishnadasan A; James Gist J; Abedi G; Fleming-Dutra KE; Chea N; Lee JE; Kellogg M; Edmundson A; Britton A; Wilson LE; Lovett SA; Ocampo V; Markus TM; Smithline HA; Hou PC; Lee LC; Mower W; Rwamwejo F; Steele MT; Lim SC; Schrading WA; Chinnock B; Beiser DG; Faine B; Haran JP; Nandi U; Chipman AK; LoVecchio F; Eucker S; Femling J; Fuller M; Rothman RE; Curlin ME; Talan DA; Mohr NM;
    Vaccine; 2024 Apr; 42(10):2543-2552. PubMed ID: 37973512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel.
    Swift MD; Breeher LE; Tande AJ; Tommaso CP; Hainy CM; Chu H; Murad MH; Berbari EF; Virk A
    Clin Infect Dis; 2021 Sep; 73(6):e1376-e1379. PubMed ID: 33900384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A SARS-CoV-2 mRNA Vaccine - Preliminary Report. Reply.
    Jackson LA; Roberts PC; Graham BS
    N Engl J Med; 2020 Sep; 383(12):1191-1192. PubMed ID: 32813942
    [No Abstract]   [Full Text] [Related]  

  • 16. Successful mRNA SARS-Cov-2 vaccine rechallenge after a first episode of immune thrombocytopenic purpura.
    Chanut M; Jaidi R; Kohn M; Grange T; Brones C; Lombion N; Rousselot P; Longval T
    Platelets; 2022 May; 33(4):652-653. PubMed ID: 35225144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Single dose of SARS-CoV-2 mRNA vaccine in post-COVID-19 elderly people].
    Nieto Colino S; Cid Abasolo FJ; Martínez Hernández J
    Rev Esp Geriatr Gerontol; 2021; 56(5):312-313. PubMed ID: 34172313
    [No Abstract]   [Full Text] [Related]  

  • 18. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
    Beckley M; Olson AK; Portman MA
    JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serologic response to a third dose of an mRNA-based SARS-CoV-2 vaccine in lung transplant recipients.
    Hoffman TW; Meek B; Rijkers GT; van Kessel DA
    Transpl Immunol; 2022 Jun; 72():101599. PubMed ID: 35390480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity.
    Bowman KA; Stein D; Shin S; Ferbas KG; Tobin NH; Mann C; Fischinger S; Ollmann Saphire E; Lauffenburger D; Rimoin AW; Aldrovandi G; Alter G
    mBio; 2022 Oct; 13(5):e0164722. PubMed ID: 36000735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.